What's coming

The most exciting idea is antigen-specific tolerance — 'inverse vaccines' that teach the immune system to stop attacking the thyroid specifically, rather than blanket immunosuppression. The proof of concept already exists in the sister disease Graves' (a peptide therapy improved ~70% of patients in an early trial); Hashimoto's-specific versions are still in the lab. And the broader autoimmune 'immune reset' (CD19 CAR-T) has produced drug-free remissions in lupus and RA — far too much for a manageable disease like Hashimoto's, but proof that antibody-driven autoimmunity can be reset. Evidence ●●○○○

The nearest-term real-world upside is for the 10–20% who don't feel well on standard levothyroxine: steadier forms of T3 are in development — slow-release and zinc-coordinated T3 that flatten the post-dose spike, and once-weekly dosing for adherence. Not a cure, but a better tool for the people levothyroxine underserves. Evidence ●●○○○

The most futuristic: lab-grown thyroid tissue. Human stem-cell-derived thyroid 'organoids' can make hormone and, transplanted into mice with no thyroid, restored their levels. It's the 'regrow the gland' dream — real lab progress, but years-to-decades from patients. Evidence ○○○○○ as a treatment today